TTR and COVID-19: Menter et al. report senile amyloidosis as confirmed by immunohistochemistry for ATTR in 6/21 (29%) of their autopsied COVID-19 patients, all aged between 76–96 years, with additional amyloid deposition in pulmonary vessels in three of them (overall: 14%) [39].